Ascendia Pharma

Shaukat Ali, PhD, Senior Director of Scientific Affairs and Technical Marketing, Ascendia Pharmaceuticals, highlights the benefits of the company’s nanotechnologies in supporting formulation development of poorly soluble molecules.

Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals, highlights traits that a (bio)pharmaceutical company look for when identifying a CDMO to support drug development and manufacturing programs.

Ascendia Pharmaceuticals CEO, Jim Huang, describes how new opportunities in formulation development complement the company’s previous work in developing novel nanotechnologies to support biopharmaceutical development.

What does Ascendia do? What sets Ascendia apart from its competitors? What is Ascendia's company culture like?

This white paper from Ascendia Pharma details four factors to consider when selecting a CDMO for your next drug development project.

This white paper from Ascendia Pharma details four factors to consider when selecting a CDMO for your next drug development project.